Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human naive CD4 T cell subsets on young and old donors

ABSTRACT: We report the application of single-molecule-based sequencing technology for high-throughput profiling of naive CD4 T cells. By sequencing this population in young and older donors, we describe the heterogeneity of Tscm CD4 cells based on differential engagement of Wnt pathways and inflammation.

ORGANISM(S): Homo sapiens

PROVIDER: GSE143213 | GEO | 2020/01/08

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Single cell RNA sequencing of human naive CD4 T cells on young and old donors

Project description:We report the application of single-molecule-based sequencing technology for high-throughput profiling of naive CD4 T cells. By sequencing this population in young and older donors, we describe the heterogeneity of Tscm CD4 cells based on differential engagement of Wnt pathways and inflammation.

2020-01-08 | GSE143214 | GEO

Human naive CD4 T cell subsets on young and old donors

Project description:Human naive CD4 T cell subsets on young and old donors

| PRJNA599312 | ENA

Response of peripheral blood mononuclear cells from young (≤ 45 years old) and old (>60 years old) healthy donors to influenza virus derived peptide stimulation.

2016-08-15 | GSE72374 | GEO

Young and old muscle comparison

Project description:RNA was pooled from vastus lateralis biopsies obtained from 8 younger (21-24 yr) and 8 older (66-77 yr)men. Healthy subjects with no neuromuscular disease. Keywords: other

2002-02-01 | GSE17 | GEO

RNAseq of old and young males with equal physical activity

Project description:18 older (65-71 years) and 20 young (19-25 years) males were recruited based on similar, self-reported physical activity, which was verified using accelerometry measurements. Gene expression profiles of vastus lateralis biopsies obtained by RNA sequencing. A clear ageing signature was observed despite similar physcical activity.

2021-10-20 | GSE159217 | GEO

Response of peripheral blood mononuclear cells from young (â¤ 45 years old) and old (>60 years old) healthy donors to influenza virus derived peptide stimulation.

Project description:CD4 T cell responses are characterized based on a limited number of molecular markers selected from exisiting knowledge. The goal of the experiment was to assess antigenic-peptide specific T-cell responses in vitro without bias using microarrays. PBMCs were isolated from 11 young (â¤ 45 years old) and old (> 60 years old) healthy donors. The cells were stimulated with peptides derived from influenza virus for 24 hours. Unstimulated cells were cultured without the peptides for 24 hours.

2016-08-15 | E-GEOD-72374 | biostudies-arrayexpress

Single cell RNA sequencing of human naive CD4 T cells on young and old donors

Project description:Single cell RNA sequencing of human naive CD4 T cells on young and old donors

| PRJNA599319 | ENA

Generation of clinical grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of B-cell malignancies

Project description:Long-lived, self-renewing, multipotent T memory stem cells (TSCM) can trigger profound and sustained tumor regression but their rareness poses a major hurdle to their clinical application. Presently, clinically compliant procedures to generate relevant numbers of this T cell population are undefined. Here, we provide a strategy for deriving large numbers of clinical grade tumor-redirected TSCM cells starting from naÃ¯ve precursors. CD8+CD62L+CD45RA+ naÃ¯ve T cells enriched by streptamer-based serial positive selection were activated by CD3/CD28 engagement in the presence of IL-7, IL-21 and the glycogen synthase-3Î² inhibitor TWS119, and genetically engineered to express a CD19-specific chimeric antigen receptor (CD19-CAR). These conditions allowed for the generation of CD19-CAR modified TSCM cells that were phenotypically, functionally and transcriptomically equivalent to their naturally occurring counterpart. Compared with T cell products currently under clinical investigation, CD19-CAR modified TSCM cells exhibit enhanced metabolic fitness, persistence and anti-tumor activity against systemic acute lymphoblastic leukemia xenografts. Based on these findings, we have initiated a phase 1 clinical study to evaluate the activity of CD19-CAR modified TSCM in patients with B-cell malignancies refractory to prior allogeneic hematopoietic stem cell transplantation. Three healthy human blood donors provided lymphocyte-enriched apheresis blood for this study after informed consent. From all samples, total RNA was isolated using an miRNeasy Mini Kit (Qiagen), processed by Ambionâ??s WT expression kit, fragmented and labeled with a WT Terminal Labeling Kit (Affymetrix), hybridized to WT Human Gene 1.0 ST arrays (Affymetrix) and stained on a Genechip Fluidics Station 450 (Affymetrix), all according to the respective manufacturer's instructions. Samples represent exon-level and gene-level analyses.

2016-06-29 | E-GEOD-68003 | biostudies-arrayexpress

Generation of clinical grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of B-cell malignancies

Project description:Long-lived, self-renewing, multipotent T memory stem cells (TSCM) can trigger profound and sustained tumor regression but their rareness poses a major hurdle to their clinical application. Presently, clinically compliant procedures to generate relevant numbers of this T cell population are undefined. Here, we provide a strategy for deriving large numbers of clinical grade tumor-redirected TSCM cells starting from naïve precursors. CD8+CD62L+CD45RA+ naïve T cells enriched by streptamer-based serial positive selection were activated by CD3/CD28 engagement in the presence of IL-7, IL-21 and the glycogen synthase-3β inhibitor TWS119, and genetically engineered to express a CD19-specific chimeric antigen receptor (CD19-CAR). These conditions allowed for the generation of CD19-CAR modified TSCM cells that were phenotypically, functionally and transcriptomically equivalent to their naturally occurring counterpart. Compared with T cell products currently under clinical investigation, CD19-CAR modified TSCM cells exhibit enhanced metabolic fitness, persistence and anti-tumor activity against systemic acute lymphoblastic leukemia xenografts. Based on these findings, we have initiated a phase 1 clinical study to evaluate the activity of CD19-CAR modified TSCM in patients with B-cell malignancies refractory to prior allogeneic hematopoietic stem cell transplantation.

2016-06-29 | GSE68003 | GEO

RNA-seq comparison of gene induction in RIG-I stimulated old and young human monocytes

Project description:Goal: The goal of this study was to compare gene induction in old and young human monocytes upon stimulation of these cells with a RIG-I specific ligand, based on previously published results which indicated impaired interferon responses in monocytes from older individuals upon influenza virus infeciton.

2017-12-31 | GSE100709 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data